Literature DB >> 6198570

High-dose intravenous gammaglobulin for myasthenia gravis.

P Gajdos, H Outin, D Elkharrat, D Brunel, P de Rohan-Chabot, J C Raphael, M Goulon, C Goulon-Goeau, E Morel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198570     DOI: 10.1016/s0140-6736(84)90469-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  33 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies.

Authors:  Melvin Berger
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

Review 3.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

4.  New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.

Authors:  Martin Stangel
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 5.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

6.  Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies.

Authors:  R Liblau; P Gajdos; F A Bustarret; R el Habib; J F Bach; E Morel
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

Review 7.  Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders.

Authors:  S A Schwartz
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

8.  Dosing and individualized treatment - patient-centric treatment: changing practice guidelines.

Authors:  H S Patwa
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 9.  Intravenous immune globulin in myasthenia gravis.

Authors:  P Gajdos
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 10.  History of Myasthenia Gravis Revisited.

Authors:  Feza Deymeer
Journal:  Noro Psikiyatr Ars       Date:  2020-11-07       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.